What is West Pharmaceutical Services, Inc.'s earnings per share (EPS)?

West Pharmaceutical Services, Inc. (WST) reported diluted earnings per share of $6.79 for fiscal year 2025. This represents a 1.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

West Pharmaceutical Services, Inc. (WST) Financials

WST

Trailing 12 months to June 30, 2026

Revenue $3.3B +12.4% YoY

Net Income $564.9M +15.8% YoY

EPS (Diluted) $7.81 +16.9% YoY

Free Cash Flow $436.9M +27.0% YoY

Market Cap $26.2B as of Oct 14, 2026

Price / Sales 7.9x on $3.3B revenue, trailing 12 months to June 30, 2026

Price / Earnings 46.3x on $564.9M net income, trailing 12 months to June 30, 2026

Price / Book 8.8x on $3.0B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 23, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 23, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the WST SEC filings page.

West Pharmaceutical Services, Inc. (WST) reported $3.3B in revenue over the twelve months to Jun 30, 2026, up 12.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI WST FY2025 2026-10-03

West's profitable, lightly leveraged manufacturing model saw cash generation recover faster than operating margins after the FY2024 setback.

From FY2021 to FY2025, gross margin fell from 41.5% to 35.9% while revenue reached a new high, pointing to cost or mix pressure rather than shrinking demand. FY2025 free cash flow reached $468.9M while capex was $285.9M, so cash conversion benefited from lighter reinvestment even though net income was nearly flat.

The balance-sheet posture remains conservative: total liabilities were just 0.3x equity, and current assets covered current liabilities by 3.0x in FY2025. Total assets expanded to $4.3B, while ROA was only 11.6%, indicating that added scale has not translated proportionally into return efficiency.

The FY2025 revenue recovery did not restore operating margin, which was 19.0% versus 26.6% in FY2021. SG&A and R&D rose to $393.6M and $74.3M, so overhead and development spending absorbed much of the rebound instead of flowing through to operating profit.

Financial Health Signals

Financial Health Score 76/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of West Pharmaceutical Services, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

West Pharmaceutical Services, Inc. has an operating margin of 19.0%, meaning the company retains $19 of operating profit per $100 of revenue. This strong profitability earns a score of 86/100, reflecting efficient cost management and pricing power. This is down from 19.7% the prior year.

Growth

West Pharmaceutical Services, Inc.'s revenue grew 6.3% year-over-year to $3.1B, a solid pace of expansion. This earns a growth score of 38/100.

Leverage

West Pharmaceutical Services, Inc. carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.02, West Pharmaceutical Services, Inc. holds $3.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 79/100.

Cash Flow

West Pharmaceutical Services, Inc. converts 15.3% of revenue into free cash flow ($468.9M). This strong cash generation earns a score of 74/100.

Returns

West Pharmaceutical Services, Inc. earns a strong 15.5% return on equity (ROE), meaning it generates $16 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 84/100. This is down from 18.4% the prior year.

Altman Z-Score Safe

17.33

West Pharmaceutical Services, Inc. scores 17.33, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($26.2B) relative to total liabilities ($1.1B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

West Pharmaceutical Services, Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.53x

For every $1 of reported earnings, West Pharmaceutical Services, Inc. generates $1.53 in operating cash flow ($754.8M OCF vs $493.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

38.74x

West Pharmaceutical Services, Inc. earns $38.74 in operating income for every $1 of interest expense ($584.9M vs $15.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$872.3M

YoY+13.8%

QoQ+3.2%

5Y CAGR+3.8%

10Y CAGR+8.4%

West Pharmaceutical Services, Inc. generated $872.3M in revenue in Q2 2026. This represents an increase of 13.8% from the same quarter a year earlier. Against the prior quarter it is up 3.2%.

EBITDA

$225.3M

YoY+15.5%

QoQ+1.3%

5Y CAGR-1.2%

West Pharmaceutical Services, Inc.'s EBITDA was $225.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.5% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.

Net Income

$154.0M

YoY+16.8%

QoQ+11.0%

5Y CAGR-3.8%

10Y CAGR+13.2%

West Pharmaceutical Services, Inc. reported $154.0M in net income in Q2 2026. This represents an increase of 16.8% from the same quarter a year earlier. Against the prior quarter it is up 11.0%.

EPS (Diluted)

$2.15

YoY+18.1%

QoQ+12.0%

5Y CAGR-2.7%

10Y CAGR+13.6%

West Pharmaceutical Services, Inc. earned $2.15 per diluted share (EPS) in Q2 2026. This represents an increase of 18.1% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.

Cash & Balance Sheet

Free Cash Flow

$80.8M

YoY-20.7%

QoQ+71.2%

5Y CAGR-1.6%

10Y CAGR+7.0%

West Pharmaceutical Services, Inc. generated $80.8M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 20.7% from the same quarter a year earlier. Against the prior quarter it is up 71.2%.

Cash & Debt

$435.8M

YoY-14.5%

QoQ-16.4%

5Y CAGR-5.4%

10Y CAGR+8.0%

West Pharmaceutical Services, Inc. held $435.8M in cash against $202.9M in long-term debt as of Q2 2026.

Shares Outstanding

70M

YoY-2.1%

QoQ-0.4%

5Y CAGR-1.0%

10Y CAGR-0.4%

West Pharmaceutical Services, Inc. had 70M shares outstanding in Q2 2026. This represents a decrease of 2.1% from the same quarter a year earlier. Against the prior quarter it is down 0.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

37.7%

YoY+2.0pp

QoQ+2.7pp

5Y change-5.8pp

10Y change+3.4pp

West Pharmaceutical Services, Inc.'s gross margin was 37.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.7 percentage points.

Operating Margin

20.5%

YoY+0.5pp

QoQ-0.4pp

5Y change-8.7pp

West Pharmaceutical Services, Inc.'s operating margin was 20.5% in Q2 2026, reflecting core business profitability. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.

Net Margin

17.6%

YoY+0.5pp

QoQ+1.2pp

5Y change-8.2pp

10Y change+6.1pp

West Pharmaceutical Services, Inc.'s net profit margin was 17.6% in Q2 2026, showing the share of revenue converted to profit. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Return on Equity

5.1%

YoY+0.6pp

QoQ+0.5pp

5Y change-4.1pp

10Y change+1.1pp

West Pharmaceutical Services, Inc.'s ROE was 5.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Capital Allocation

R&D Spending

$19.7M

YoY+3.1%

QoQ+24.7%

5Y CAGR+7.4%

West Pharmaceutical Services, Inc. invested $19.7M in research and development in Q2 2026. This represents an increase of 3.1% from the same quarter a year earlier. Against the prior quarter it is up 24.7%.

Share Buybacks

$156.7M

YoY+31240.0%

QoQ-47.3%

10Y CAGR+34.5%

West Pharmaceutical Services, Inc. spent $156.7M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 31240.0% from the same quarter a year earlier. Against the prior quarter it is down 47.3%.

Capital Expenditures

$43.2M

YoY-42.6%

QoQ+1.2%

5Y CAGR-5.4%

10Y CAGR+2.1%

West Pharmaceutical Services, Inc. invested $43.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 42.6% from the same quarter a year earlier. Against the prior quarter it is up 1.2%.

WST Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WST quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.3B	$3.1B+6.3%	$2.9B-1.9%	$2.9B+2.2%	$2.9B+2.0%	$2.8B+31.9%	$2.1B+16.7%	$1.8B+7.1%	$1.7B+7.4%	$1.6B+6.0%	$1.5B+7.8%	$1.4B-1.5%	$1.4B+3.9%	$1.4B+8.1%	$1.3B+6.2%	$1.2B
Cost of Revenue	$2.1B	$2.0B+4.0%	$1.9B+4.1%	$1.8B+4.0%	$1.8B+5.7%	$1.7B+20.1%	$1.4B+11.7%	$1.2B+5.3%	$1.2B+7.9%	$1.1B+7.8%	$1.0B+6.7%	$944.0M-3.0%	$973.6M+4.3%	$933.7M+6.3%	$878.7M+3.0%	$853.0M
Gross Profit	$1.2B	$1.1B+10.6%	$998.5M-11.6%	$1.1B-0.6%	$1.1B-3.4%	$1.2B+53.1%	$767.8M+26.8%	$605.7M+11.1%	$545.4M+6.3%	$512.9M+2.3%	$501.4M+10.0%	$455.8M+1.8%	$447.8M+3.0%	$434.7M+12.1%	$387.7M+14.3%	$339.3M
R&D Expenses	$74.4M	$74.3M+7.5%	$69.1M+1.0%	$68.4M+16.9%	$58.5M+10.8%	$52.8M+12.6%	$46.9M+20.6%	$38.9M-3.5%	$40.3M+3.1%	$39.1M+6.3%	$36.8M+7.9%	$34.1M-8.6%	$37.3M-1.6%	$37.9M+14.2%	$33.2M+14.1%	$29.1M
SG&A Expenses	$426.8M	$393.6M+16.3%	$338.5M-4.2%	$353.4M+11.5%	$316.9M-12.7%	$362.8M+20.1%	$302.0M+10.7%	$272.7M+3.7%	$262.9M+6.9%	$246.0M+2.7%	$239.6M+2.8%	$233.0M+1.9%	$228.7M-2.6%	$234.9M+7.7%	$218.1M+14.1%	$191.1M
Operating Income	$680.4M	$584.9M+2.6%	$569.9M-15.7%	$676.0M-7.9%	$734.0M-2.4%	$752.3M+84.9%	$406.9M+37.2%	$296.6M+23.4%	$240.3M+6.4%	$225.8M+15.7%	$195.2M+51.8%	$128.6M-29.3%	$182.0M+12.1%	$162.4M+20.2%	$135.1M+23.3%	$109.6M
EBITDA	N/A	$756.3M+4.3%	$725.3M-10.8%	$813.3M-4.8%	$854.6M-2.3%	$874.6M+69.5%	$516.0M+29.0%	$400.0M+16.0%	$344.7M+6.9%	$322.5M+12.8%	$285.9M+30.8%	$218.5M-19.7%	$272.0M+9.9%	$247.6M+16.8%	$212.0M+14.4%	$185.3M
Interest Expense	$19.1M	$15.1M-6.8%	$16.2M+80.0%	$9.0M+13.9%	$7.9M-3.7%	$8.2M0.0%	$8.2M-3.5%	$8.5M+1.2%	$8.4M+7.7%	$7.8M-3.7%	$8.1M-42.6%	$14.1M-14.5%	$16.5M-2.9%	$17.0M+1.8%	$16.7M-8.2%	$18.2M
Income Tax	$144.2M	$121.6M+13.1%	$107.5M-12.1%	$122.3M+6.6%	$114.7M+7.0%	$107.2M+47.9%	$72.5M+22.9%	$59.0M+42.5%	$41.4M-48.8%	$80.9M+48.7%	$54.4M+106.8%	$26.3M-44.3%	$47.2M+17.4%	$40.2M+22.9%	$32.7M+39.1%	$23.5M
Net Income	$564.9M	$493.7M+0.2%	$492.7M-17.0%	$593.4M+1.3%	$585.9M-11.5%	$661.8M+91.2%	$346.2M+43.2%	$241.7M+16.8%	$206.9M+37.3%	$150.7M+4.9%	$143.6M+50.2%	$95.6M-24.8%	$127.1M+13.2%	$112.3M+39.2%	$80.7M+6.9%	$75.5M
EPS (Basic)	N/A	$6.83+1.2%	$6.75-15.4%	$7.98+1.4%	$7.87-11.5%	$8.89+90.0%	$4.68+43.1%	$3.27+16.8%	$2.80+37.3%	$2.04+4.1%	$1.96+47.4%	$1.33-25.7%	$1.79+11.2%	$1.61+35.3%	$1.19+6.2%	$1.12
EPS (Diluted)	$7.81	$6.79+1.5%	$6.69-15.1%	$7.88+1.9%	$7.73-10.8%	$8.67+89.7%	$4.57+42.4%	$3.21+17.2%	$2.74+37.7%	$1.99+4.2%	$1.91+46.9%	$1.30-25.7%	$1.75+11.5%	$1.57	$1.15+6.5%	$1.08
Diluted Shares (Avg)	N/A	73M-1.4%	74M-2.1%	75M-0.7%	76M-0.7%	76M+0.7%	76M+0.5%	75M0.0%	75M-0.5%	76M+1.1%	75M+1.6%	74M+1.4%	73M+2.0%	71M	72M-3.0%	74M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$872.3M+13.8%	$844.9M+21.0%	$805.0M+7.5%	$804.6M+7.7%	$766.5M+9.2%	$698.0M+0.4%	$748.8M+2.3%	$746.9M-0.1%
Cost of Revenue	$543.1M+10.3%	$548.5M+17.7%	$501.1M+5.5%	$510.3M+5.8%	$492.6M+4.3%	$466.1M+0.2%	$475.2M+4.7%	$482.2M+5.0%
Gross Profit	$329.2M+20.2%	$296.4M+27.8%	$303.9M+11.1%	$294.3M+11.2%	$273.9M+19.1%	$231.9M+0.7%	$273.6M-1.7%	$264.7M-8.2%
R&D Expenses	$19.7M+3.1%	$15.8M-3.1%	$21.8M+17.8%	$17.1M+10.3%	$19.1M+9.1%	$16.3M-7.4%	$18.5M+0.5%	$15.5M-5.5%
SG&A Expenses	$117.6M+22.6%	$99.5M+13.1%	$107.0M+25.4%	$102.7M+23.0%	$95.9M+15.5%	$88.0M+1.5%	$85.3M-5.2%	$83.5M-6.2%
Operating Income	$179.1M+16.5%	$177.1M+65.5%	$156.6M-1.9%	$167.6M+3.9%	$153.7M+21.8%	$107.0M-12.9%	$159.6M-0.8%	$161.3M-9.0%
EBITDA	$225.3M+15.5%	$222.3M+51.2%	$203.6M+1.6%	$210.6M+4.5%	$195.1M+18.2%	$147.0M-7.2%	$200.3M+0.6%	$201.5M-5.0%
Interest Expense	$2.6M+2500.0%	$1.9M+375.0%	$14.4M+16.1%	$200K-71.4%	$100K-93.3%	$400K-75.0%	$12.4M+933.3%	$700K-75.9%
Income Tax	$32.2M+6.6%	$44.7M+85.5%	$33.3M-9.5%	$34.0M+4.9%	$30.2M+37.9%	$24.1M+47.0%	$36.8M+6.7%	$32.4M+10.2%
Net Income	$154.0M+16.8%	$138.8M+54.6%	$132.1M+1.5%	$140.0M+2.9%	$131.8M+18.4%	$89.8M-22.1%	$130.1M-5.0%	$136.0M-15.7%
EPS (Basic)	$2.17+19.2%	$1.93+55.6%	$1.83+2.2%	$1.94+3.7%	$1.82+19.7%	$1.24-21.0%	$1.79-3.2%	$1.87-13.8%
EPS (Diluted)	$2.15+18.1%	$1.92+56.1%	$1.82+2.2%	$1.92+3.8%	$1.82+20.5%	$1.23-20.6%	$1.78-2.7%	$1.85-13.6%
Diluted Shares (Avg)	71M-1.7%	72M-0.8%	N/A	73M-1.1%	73M-1.6%	73M-1.7%	N/A	73M-2.5%

WST Balance Sheet

WST quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$4.3B+17.2%	$3.6B-4.9%	$3.8B+5.9%	$3.6B+9.1%	$3.3B+18.6%	$2.8B+19.3%	$2.3B+18.3%	$2.0B+6.2%	$1.9B+8.5%	$1.7B+1.3%	$1.7B+1.5%	$1.7B0.0%	$1.7B+6.8%	$1.6B+11.8%	$1.4B
Current Assets	$2.0B+28.6%	$1.5B-20.6%	$1.9B+0.9%	$1.9B+10.2%	$1.7B+26.8%	$1.4B+29.8%	$1.1B+18.4%	$894.4M+20.3%	$743.5M+15.8%	$641.9M-4.7%	$673.7M+2.2%	$659.1M+1.3%	$650.7M+16.8%	$557.3M+18.1%	$472.0M
Cash & Equivalents	$791.3M+63.3%	$484.6M-43.2%	$853.9M-4.5%	$894.3M+17.3%	$762.6M+23.9%	$615.5M+40.2%	$439.1M+30.1%	$337.4M+43.0%	$235.9M+16.2%	$203.0M-26.1%	$274.6M+7.6%	$255.3M+11.0%	$230.0M+42.1%	$161.9M+76.4%	$91.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$7.5M-39.5%	$12.4M-53.2%	$26.5M
Inventory	$443.9M+17.7%	$377.0M-13.3%	$434.7M+4.8%	$414.8M+9.6%	$378.4M+17.8%	$321.3M+36.3%	$235.7M+9.9%	$214.5M-0.3%	$215.2M+8.0%	$199.3M+10.0%	$181.1M-0.2%	$181.5M+2.6%	$176.9M+9.1%	$162.2M+6.9%	$151.8M
Accounts Receivable	$574.4M+4.0%	$552.5M+7.9%	$512.0M+0.9%	$507.4M+3.8%	$489.0M+26.9%	$385.3M+20.7%	$319.3M+10.8%	$288.2M+13.8%	$253.2M+26.3%	$200.5M+10.5%	$181.4M+1.3%	$179.0M-3.6%	$185.7M+6.1%	$175.0M+18.9%	$147.2M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$109.9M+3.7%	$106.0M-2.3%	$108.5M+1.1%	$107.3M-2.4%	$109.9M-1.1%	$111.1M+3.1%	$107.8M+1.9%	$105.8M-1.8%	$107.7M+4.6%	$103.0M-1.5%	$104.6M-3.7%	$108.6M-4.9%	$114.2M+1.5%	$112.5M+0.9%	$111.5M
Total Liabilities	$1.1B+13.8%	$961.1M+1.3%	$948.5M+1.8%	$931.9M-4.8%	$978.4M+4.2%	$939.3M+22.3%	$768.2M+31.9%	$582.6M-0.1%	$582.9M-2.7%	$599.2M-10.7%	$671.2M-5.8%	$712.8M-6.8%	$765.2M-8.4%	$835.1M+12.2%	$744.2M
Current Liabilities	$654.9M+19.0%	$550.4M-18.1%	$671.8M+29.4%	$519.0M-12.6%	$594.1M+18.0%	$503.4M+47.4%	$341.6M+20.4%	$283.7M+1.5%	$279.5M+16.0%	$241.0M-23.3%	$314.3M+24.5%	$252.5M+6.6%	$236.9M-9.5%	$261.8M+7.6%	$243.2M
Non-Current Liabilities	$439.1M+6.9%	$410.7M+48.4%	$276.7M-33.0%	$412.9M+7.4%	$384.3M-11.8%	$435.9M+2.2%	$426.6M+42.7%	$298.9M-1.5%	$303.4M-15.3%	$358.2M+0.4%	$356.9M-22.5%	$460.3M-12.9%	$528.3M-7.8%	$573.3M+14.4%	$501.0M
Long-Term Debt	$202.8M+0.1%	$202.6M+178.3%	$72.8M-64.8%	$206.7M-1.0%	$208.8M-17.4%	$252.9M-0.8%	$255.0M+30.1%	$196.0M-0.5%	$197.0M-12.9%	$226.2M-1.2%	$228.9M-25.8%	$308.3M-17.0%	$371.3M-2.0%	$378.8M+26.6%	$299.3M
Total Equity	$3.2B+18.4%	$2.7B-6.9%	$2.9B+7.3%	$2.7B+15.0%	$2.3B+25.9%	$1.9B+17.9%	$1.6B+12.7%	$1.4B+9.1%	$1.3B+14.5%	$1.1B+9.1%	$1.0B+7.0%	$956.9M+5.6%	$906.4M+24.4%	$728.9M+11.3%	$654.9M
Retained Earnings	$4.4B+10.6%	$4.0B+12.3%	$3.5B+17.9%	$3.0B+21.6%	$2.5B+33.0%	$1.8B+19.2%	$1.5B+14.5%	$1.4B+14.9%	$1.2B+9.9%	$1.1B+11.1%	$964.6M+6.9%	$902.2M+12.1%	$805.0M+11.8%	$719.9M+8.3%	$664.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$4.1B+3.1%	$4.1B+13.6%	$4.3B+17.2%	$4.1B+11.7%	$4.0B+13.3%	$3.6B+0.4%	$3.6B-4.9%	$3.7B-2.1%
Current Assets	$1.8B+7.5%	$1.8B+25.3%	$2.0B+28.6%	$1.8B+17.6%	$1.7B+13.3%	$1.5B-13.9%	$1.5B-20.6%	$1.6B-21.4%
Cash & Equivalents	$435.8M-14.5%	$521.4M+29.0%	$791.3M+63.3%	$628.5M+28.0%	$509.7M+14.2%	$404.2M-32.8%	$484.6M-43.2%	$490.9M-45.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$447.4M+6.2%	$452.6M+16.4%	$443.9M+17.7%	$438.0M+9.2%	$421.1M+0.5%	$388.7M-9.6%	$377.0M-13.3%	$401.2M-7.1%
Accounts Receivable	$712.0M+22.3%	$685.6M+26.1%	$574.4M+4.0%	$625.0M+19.2%	$582.4M+21.5%	$543.6M+3.7%	$552.5M+7.9%	$524.3M+1.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$108.7M-2.0%	$109.2M+1.6%	$109.9M+3.7%	$110.6M+1.7%	$110.9M+3.4%	$107.5M-0.1%	$106.0M-2.3%	$108.8M+1.9%
Total Liabilities	$1.1B+6.1%	$1.1B+19.7%	$1.1B+13.8%	$1.1B+14.2%	$1.0B+12.2%	$935.1M+1.5%	$961.1M+1.3%	$923.0M+4.1%
Current Liabilities	$640.5M+5.9%	$674.0M+28.0%	$654.9M+19.0%	$635.4M+23.0%	$604.6M-4.6%	$526.7M-18.8%	$550.4M-18.1%	$516.5M-3.2%
Non-Current Liabilities	$445.7M+6.3%	$445.4M+9.1%	$439.1M+6.9%	$418.9M+3.1%	$419.1M+50.3%	$408.4M+49.4%	$410.7M+48.4%	$406.5M+15.2%
Long-Term Debt	$202.9M+0.1%	$202.8M+0.1%	$202.8M+0.1%	$202.7M0.0%	$202.6M+177.9%	$202.6M+178.3%	$202.6M+178.3%	$202.6M+33.2%
Total Equity	$3.0B+2.1%	$3.0B+11.5%	$3.2B+18.4%	$3.1B+10.9%	$2.9B+13.7%	$2.7B+0.1%	$2.7B-6.9%	$2.8B-4.0%
Retained Earnings	$4.6B+11.7%	$4.5B+11.0%	$4.4B+10.6%	$4.3B+10.5%	$4.1B+11.2%	$4.0B+11.2%	$4.0B+12.3%	$3.9B+12.9%

WST Cash Flow Statement

WST quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$662.2M	$754.8M+15.5%	$653.4M-15.9%	$776.5M+7.3%	$724.0M+24.0%	$584.0M+23.6%	$472.5M+28.7%	$367.2M+27.2%	$288.6M+9.6%	$263.3M+20.0%	$219.4M+3.3%	$212.4M+16.1%	$182.9M-17.1%	$220.5M+17.7%	$187.4M+43.4%	$130.7M
Depreciation & Amortization	N/A	$171.4M+10.3%	$155.4M+13.2%	$137.3M+13.8%	$120.6M-1.4%	$122.3M+12.1%	$109.1M+5.5%	$103.4M-1.0%	$104.4M+8.0%	$96.7M+6.6%	$90.7M+0.9%	$89.9M-0.1%	$90.0M+5.6%	$85.2M+10.8%	$76.9M+1.6%	$75.7M
Stock-Based Compensation	N/A	$23.8M+27.3%	$18.7M-19.7%	$23.3M-1.7%	$23.7M-36.8%	$37.5M+10.3%	$34.0M+39.3%	$24.4M+61.6%	$15.1M-6.2%	$16.1M-17.4%	$19.5M-34.1%	$29.6M+59.1%	$18.6M-12.3%	$21.2M+36.8%	$15.5M+84.5%	$8.4M
Capital Expenditures	$225.3M	$285.9M-24.2%	$377.0M+4.1%	$362.0M+27.2%	$284.6M+12.3%	$253.4M+45.3%	$174.4M+38.0%	$126.4M+20.7%	$104.7M-20.0%	$130.8M-23.1%	$170.2M+29.3%	$131.6M+17.6%	$111.9M-26.3%	$151.9M+15.7%	$131.3M+37.6%	$95.4M
Free Cash Flow	$436.9M	$468.9M+69.6%	$276.4M-33.3%	$414.5M-5.7%	$439.4M+32.9%	$330.6M+10.9%	$298.1M+23.8%	$240.8M+30.9%	$183.9M+38.8%	$132.5M+169.3%	$49.2M-39.1%	$80.8M+13.8%	$71.0M+3.5%	$68.6M+22.3%	$56.1M+58.9%	$35.3M
Investing Cash Flow	-$225.3M	-$285.9M+24.5%	-$378.7M-2.7%	-$368.7M-27.9%	-$288.2M-13.9%	-$253.1M-41.0%	-$179.5M+21.3%	-$228.0M-126.2%	-$100.8M+24.6%	-$133.6M+24.0%	-$175.8M-35.8%	-$129.5M-24.5%	-$104.0M+30.6%	-$149.9M-29.2%	-$116.0M+3.7%	-$120.5M
Financing Cash Flow	-$496.7M	-$185.1M+70.3%	-$622.6M-35.5%	-$459.6M-56.5%	-$293.6M-74.7%	-$168.1M-22.6%	-$137.1M-272.6%	-$36.8M+54.4%	-$80.7M+26.0%	-$109.0M+4.3%	-$113.9M-174.5%	-$41.5M-34.7%	-$30.8M-503.9%	-$5.1M-50.0%	-$3.4M+86.2%	-$24.7M
Dividends Paid	$62.4M	$61.2M+3.6%	$59.1M+3.7%	$57.0M+5.4%	$54.1M+5.9%	$51.1M+6.2%	$48.1M+6.7%	$45.1M+7.1%	$42.1M+7.7%	$39.1M+9.2%	$35.8M+10.5%	$32.4M+11.3%	$29.1M+9.0%	$26.7M+7.2%	$24.9M+7.3%	$23.2M
Share Buybacks	$454.3M	$134.0M-76.1%	$560.9M+28.0%	$438.3M+116.1%	$202.8M+47.9%	$137.1M+18.7%	$115.5M+39.0%	$83.1M+17.4%	$70.8M-4.8%	$74.4M+42.5%	$52.2M	$0	$0	N/A	$4.7M+34.3%	$3.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$124.0M-30.0%	$89.9M-30.5%	$251.1M+32.1%	$197.2M+9.5%	$177.1M+7.3%	$129.4M+9.5%	$190.1M-20.5%	$180.1M-21.7%
Depreciation & Amortization	$46.2M+11.6%	$45.2M+13.0%	$47.0M+15.5%	$43.0M+7.0%	$41.4M+6.4%	$40.0M+12.4%	$40.7M+6.5%	$40.2M+15.5%
Stock-Based Compensation	$10.9M+47.3%	$6.6M+407.7%	N/A	$8.4M+64.7%	$7.4M+72.1%	$1.3M-74.0%	N/A	$5.1M-13.6%
Capital Expenditures	$43.2M-42.6%	$42.7M-40.1%	$76.1M-27.5%	$63.3M-22.1%	$75.2M-25.0%	$71.3M-21.3%	$104.9M-3.5%	$81.3M-15.1%
Free Cash Flow	$80.8M-20.7%	$47.2M-18.8%	$175.0M+105.4%	$133.9M+35.5%	$101.9M+57.3%	$58.1M+110.5%	$85.2M-34.7%	$98.8M-26.4%
Investing Cash Flow	-$43.2M+42.6%	-$42.7M+40.1%	-$76.1M+27.4%	-$63.3M+22.9%	-$75.2M+25.7%	-$71.3M+21.3%	-$104.8M+3.7%	-$82.1M+14.2%
Financing Cash Flow	-$164.8M-1006.0%	-$308.7M-110.0%	-$11.7M+83.0%	-$11.5M+82.1%	-$14.9M+93.2%	-$147.0M+45.8%	-$68.9M+63.6%	-$64.4M-188.8%
Dividends Paid	$15.7M+4.0%	$15.8M+3.9%	$15.8M+3.3%	$15.1M+4.1%	$15.1M+3.4%	$15.2M+3.4%	$15.3M+3.4%	$14.5M+3.6%
Share Buybacks	$156.7M+31240.0%	$297.6M+122.9%	$0-100.0%	$0-100.0%	$500K-99.7%	$133.5M-50.0%	$54.4M-69.3%	$52.4M+88.5%

WST Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WST quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	35.9%+1.4pp	34.5%-3.8pp	38.3%-1.1pp	39.4%-2.2pp	41.5%+5.8pp	35.8%+2.8pp	32.9%+1.2pp	31.8%-0.3pp	32.1%-1.2pp	33.2%+0.7pp	32.6%+1.1pp	31.5%-0.3pp	31.8%+1.2pp	30.6%+2.1pp	28.5%
Operating Margin	19.0%-0.7pp	19.7%-3.2pp	22.9%-2.5pp	25.4%-1.1pp	26.6%+7.6pp	18.9%+2.8pp	16.1%+2.1pp	14.0%-0.1pp	14.1%+1.2pp	12.9%+3.7pp	9.2%-3.6pp	12.8%+0.9pp	11.9%+1.2pp	10.7%+1.5pp	9.2%
Net Margin	16.1%-1.0pp	17.0%-3.1pp	20.1%-0.2pp	20.3%-3.1pp	23.4%+7.2pp	16.1%+3.0pp	13.1%+1.1pp	12.0%+2.6pp	9.4%-0.1pp	9.5%+2.7pp	6.8%-2.1pp	8.9%+0.7pp	8.2%+1.8pp	6.4%0.0pp	6.3%
Return on Equity	15.5%-2.8pp	18.4%-2.2pp	20.6%-1.2pp	21.8%-6.5pp	28.3%+9.7pp	18.7%+3.3pp	15.4%+0.5pp	14.8%+3.0pp	11.8%-1.1pp	12.8%+3.5pp	9.3%-3.9pp	13.3%+0.9pp	12.4%+1.3pp	11.1%-0.5pp	11.5%
Return on Assets	11.6%-2.0pp	13.5%-2.0pp	15.5%-0.7pp	16.2%-3.8pp	20.0%+7.6pp	12.4%+2.1pp	10.3%-0.1pp	10.5%+2.4pp	8.1%-0.3pp	8.4%+2.7pp	5.6%-2.0pp	7.6%+0.9pp	6.7%+1.6pp	5.2%-0.2pp	5.4%
Current Ratio	3.02+0.2x	2.79-0.1x	2.88-0.8x	3.70+0.8x	2.93+0.2x	2.73-0.4x	3.10-0.1x	3.15+0.5x	2.660.0x	2.66+0.5x	2.14-0.5x	2.61-0.1x	2.75+0.6x	2.13+0.2x	1.94
Debt-to-Equity	0.060.0x	0.08+0.1x	0.03-0.1x	0.080.0x	0.090.0x	0.140.0x	0.160.0x	0.140.0x	0.150.0x	0.200.0x	0.22-0.1x	0.32-0.1x	0.41-0.1x	0.52+0.1x	0.46
Asset Turnover	0.72-0.1x	0.790.0x	0.770.0x	0.80-0.1x	0.85+0.1x	0.770.0x	0.79-0.1x	0.870.0x	0.860.0x	0.88+0.1x	0.830.0x	0.850.0x	0.820.0x	0.810.0x	0.85
FCF Margin	15.3%+5.7pp	9.6%-4.5pp	14.1%-1.2pp	15.2%+3.5pp	11.7%-2.2pp	13.9%+0.8pp	13.1%+2.4pp	10.7%+2.4pp	8.3%+5.0pp	3.3%-2.5pp	5.8%+0.8pp	5.0%0.0pp	5.0%+0.6pp	4.4%+1.5pp	3.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	37.7%+2.0pp	35.1%+1.9pp	37.8%+1.2pp	36.6%+1.1pp	35.7%+3.0pp	33.2%+0.1pp	36.5%-1.5pp	35.4%-3.1pp
Operating Margin	20.5%+0.5pp	21.0%+5.6pp	19.4%-1.9pp	20.8%-0.8pp	20.1%+2.1pp	15.3%-2.3pp	21.3%-0.7pp	21.6%-2.1pp
Net Margin	17.6%+0.5pp	16.4%+3.6pp	16.4%-1.0pp	17.4%-0.8pp	17.2%+1.3pp	12.9%-3.7pp	17.4%-1.4pp	18.2%-3.4pp
Return on Equity	5.1%+0.6pp	4.6%+1.3pp	4.2%-0.7pp	4.6%-0.3pp	4.5%+0.2pp	3.4%-0.9pp	4.9%+0.1pp	4.9%-0.7pp
Return on Assets	3.8%+0.4pp	3.4%+0.9pp	3.1%-0.5pp	3.4%-0.3pp	3.3%+0.1pp	2.5%-0.7pp	3.6%0.0pp	3.7%-0.6pp
Current Ratio	2.820.0x	2.71-0.1x	3.02+0.2x	2.87-0.1x	2.78+0.4x	2.77+0.2x	2.79-0.1x	3.00-0.7x
Debt-to-Equity	0.070.0x	0.070.0x	0.060.0x	0.070.0x	0.070.0x	0.080.0x	0.08+0.1x	0.070.0x
Asset Turnover	0.210.0x	0.210.0x	0.190.0x	0.200.0x	0.190.0x	0.190.0x	0.210.0x	0.200.0x
FCF Margin	9.3%-4.0pp	5.6%-2.7pp	21.7%+10.4pp	16.6%+3.4pp	13.3%+4.1pp	8.3%+4.3pp	11.4%-6.4pp	13.2%-4.7pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
West Pharmaceutical Services, Inc. WST	FY2025	$3.1B	$493.7M	16.1%	$26.2B	76/100
Hologic Inc HOLX	FY2025	$4.1B	$565.7M	13.8%	$17.0B	69/100
Baxter International Inc. BAX	FY2025	$11.2B	-$957.0M	-8.5%	$12.9B	36/100
Solventum Corporation SOLV	FY2025	$8.3B	$1.6B	18.7%	$14.7B	50/100
The Cooper Companies, Inc. COO	FY2025	$4.1B	$374.9M	9.2%	$10.4B	59/100
ResMed Inc. RMD	FY2026	$5.7B	$1.5B	26.9%	$33.1B	87/100

Where West Pharmaceutical Services, Inc. Ranks

Frequently Asked Questions

What is West Pharmaceutical Services, Inc.'s annual revenue?

West Pharmaceutical Services, Inc. (WST) reported $3.1B in total revenue for fiscal year 2025. This represents a 6.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is West Pharmaceutical Services, Inc.'s revenue growing?

West Pharmaceutical Services, Inc. (WST) revenue grew by 6.3% year-over-year, from $2.9B to $3.1B in fiscal year 2025.

Is West Pharmaceutical Services, Inc. profitable?

Yes, West Pharmaceutical Services, Inc. (WST) reported a net income of $493.7M in fiscal year 2025, with a net profit margin of 16.1%.

What is West Pharmaceutical Services, Inc.'s EBITDA?

West Pharmaceutical Services, Inc. (WST) had EBITDA of $756.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does West Pharmaceutical Services, Inc. have?

As of fiscal year 2025, West Pharmaceutical Services, Inc. (WST) had $791.3M in cash and equivalents against $202.8M in long-term debt.

What is West Pharmaceutical Services, Inc.'s gross margin?

West Pharmaceutical Services, Inc. (WST) had a gross margin of 35.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is West Pharmaceutical Services, Inc.'s operating margin?

West Pharmaceutical Services, Inc. (WST) had an operating margin of 19.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is West Pharmaceutical Services, Inc.'s net profit margin?

West Pharmaceutical Services, Inc. (WST) had a net profit margin of 16.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does West Pharmaceutical Services, Inc. pay dividends?

Yes, West Pharmaceutical Services, Inc. (WST) paid $0.86 per share in dividends during fiscal year 2025.

What is West Pharmaceutical Services, Inc.'s return on equity (ROE)?

West Pharmaceutical Services, Inc. (WST) has a return on equity of 15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is West Pharmaceutical Services, Inc.'s free cash flow?

West Pharmaceutical Services, Inc. (WST) generated $468.9M in free cash flow during fiscal year 2025. This represents a 69.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is West Pharmaceutical Services, Inc.'s operating cash flow?

West Pharmaceutical Services, Inc. (WST) generated $754.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are West Pharmaceutical Services, Inc.'s total assets?

West Pharmaceutical Services, Inc. (WST) had $4.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are West Pharmaceutical Services, Inc.'s capital expenditures?

West Pharmaceutical Services, Inc. (WST) invested $285.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does West Pharmaceutical Services, Inc. spend on research and development?

West Pharmaceutical Services, Inc. (WST) invested $74.3M in research and development during fiscal year 2025.

Does West Pharmaceutical Services, Inc. buy back shares?

Yes, West Pharmaceutical Services, Inc. (WST) spent $134.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does West Pharmaceutical Services, Inc. have outstanding?

West Pharmaceutical Services, Inc. (WST) had 72M shares outstanding as of fiscal year 2025.

What is West Pharmaceutical Services, Inc.'s current ratio?

West Pharmaceutical Services, Inc. (WST) had a current ratio of 3.02 as of fiscal year 2025, which is generally considered healthy.

What is West Pharmaceutical Services, Inc.'s debt-to-equity ratio?

West Pharmaceutical Services, Inc. (WST) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is West Pharmaceutical Services, Inc.'s return on assets (ROA)?

West Pharmaceutical Services, Inc. (WST) had a return on assets of 11.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is West Pharmaceutical Services, Inc.'s P/E ratio?

West Pharmaceutical Services, Inc. (WST) trades at 46.3x earnings, its market capitalization divided by net income of $564.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $26.2B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is West Pharmaceutical Services, Inc.'s price-to-sales ratio?

West Pharmaceutical Services, Inc. (WST) trades at 7.9x sales, its market capitalization divided by revenue of $3.3B revenue, trailing 12 months to June 30, 2026. The market capitalization is $26.2B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is West Pharmaceutical Services, Inc.'s Altman Z-Score?

West Pharmaceutical Services, Inc. (WST) has an Altman Z-Score of 17.33, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is West Pharmaceutical Services, Inc.'s Piotroski F-Score?

West Pharmaceutical Services, Inc. (WST) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are West Pharmaceutical Services, Inc.'s earnings high quality?

West Pharmaceutical Services, Inc. (WST) has an earnings quality ratio of 1.53x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can West Pharmaceutical Services, Inc. cover its interest payments?

West Pharmaceutical Services, Inc. (WST) has an interest coverage ratio of 38.74x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is West Pharmaceutical Services, Inc.?

West Pharmaceutical Services, Inc. (WST) scores 76 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.